BioStock: Xintela's CEO comments on the positive patent notice

Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases. At the end of October, Xintela announced that the European Patent Office (EPO) has issued an ”Intention to grant” for the patent application covering the company’s stem cell product XSTEM. Once the patent is approved, the stem cell product will be protected on the European market for at least another 18 years. BioStock has contacted Evy Lundgren-Åkerlund, CEO of Xintela, to find out more about XSTEM and the patent.

Read the full article at biostock.se:

https://www.biostock.se/en/xintelas-ceo-comments-on-the-positive-patent-notice/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se